Diabetes

By Jonah Comstock January 8, 2019
Ascensia Diabetes Care, the Swiss tech company originally formed a few years ago from a merger of Bayer Health’s diabetes division and Panasonic Healthcare, is officially moving into the CGM space via a partnership with Huzhou, China-based Zhejiang POCTech. In the short term, the partnership will put an Ascensia-branded version of POCTech’s CE-Marked CGM in several markets by the end of the year...
By Jonah Comstock January 8, 2019
Omada Health will launch new programs for customers with depression and anxiety, the company announced yesterday. The company has entered into a perpetual licensing agreement with Lantern Health, a digital mental health company that shut down its commercial operations last August, and will integrate Lantern’s software into its existing infrastructure. Additionally, a few members of Lantern’s team...
By Dave Muoio January 3, 2019
Sugar.IQ — the digital diabetes assistant for Guardian Connect system users that is jointly supported by Medtronic and IBM Watson — has a new feature that uses artificial intelligence to predict future low glucose events. Called IQcast, the feature tells users whether they have a low, medium or high chance of dropping below the target blood glucose range within the next one to four hours. These...
By Dave Muoio December 13, 2018
Onduo, a Verily-Sanofi joint venture focused on digitally-driven diabetes management, is looking to further protect its members from foot ulcers and limb loss. Orpyx Medical Technologies’ diabetic foot ulcer sensors for its members. Thanks to a newly announced deal struck between the companies, Orpyx Medical Technologies’ FDA-cleared SurroSense Rx system will be available to “select members” of...
By Jonah Comstock November 16, 2018
Four years after announcing an ambitious — and often ridiculed — project to create a glucose-sensing lens along with Novartis subsidiary Alcon, Alphabet's Verily is throwing in the towel, the company announced in a blog post today. It will continue to work on two other medical lens projects, aimed at presbyopia and cataract surgery recovery. "Our clinical work on the glucose-...
By Jonah Comstock November 1, 2018
Just a short while after securing a CE Mark for its second generation device, Abbott has been granted FDA clearance for FreeStyle LibreLink, a companion mobile app for its 10 to 14-day CGM. The launch adds a long-awaited feature for US users that’s been available for some time in Europe: users will be able to scan their sensors with an app on their smartphone — and see their latest reading —...
By Dave Muoio October 3, 2018
Pediatric and adult Type 1 diabetes patients receiving a hybrid closed-loop artificial pancreas therapy demonstrated improved glucose control and lower risk of hypoglycemia compared to those managing their own glucose levels with an insulin pump and continuous glucose monitor, according to a study published today in the Lancet. The investigation, which was supported by JDRF and presented at the...

The Freestyle Libre 1.

By Jonah Comstock October 1, 2018
Abbott has received CE Mark clearance for the second generation of its Freestyle Libre device, which will allow the company to make the device available to users in Europe. It will be rolled out gradually in Europe starting in the next few weeks, and it will be offered as the same price as the first generation device. Freestyle Libre 1, which has been available in Europe since 2014, is a fully...
By Dave Muoio September 6, 2018
Diabetes is a costly chronic condition, and according to the International Diabetes Federation affects at least 425 million people worldwide. As such, it’s little surprise that an increasing number of digital health companies have spotted an opportunity to help patients manage and control their disease. In fact, that opportunity led the total revenue digital diabetes market to triple in 2017 to $...
By Jonah Comstock September 5, 2018
Correction: A previous version of this article failed to specify that the deal concerns Freestyle Libre Pro, rather than the consumer version, Freestyle Libre. Livongo Health, the digital chronic disease management company founded by former Allscripts CEO Glen Tullman, announced today that it will be the first United States enterprise diabetes management company to bring Abbott’s Freestyle Libre...

Editor's Pick

steroid-pharm.com

http://steroid-pharm.com

виагра инструкция цена